Sumitomo Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
- Conditions
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT03231800
- Locations
- 🇺🇸
Avida Inc, Newport Beach, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸South Shore Psychiatric Services PC, Hingham, Massachusetts, United States
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
- Conditions
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03187301
- Locations
- 🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 221
- Registration Number
- NCT03149003
- Locations
- 🇺🇸
Piedmont brain tumor center, Atlanta, Georgia, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
- Conditions
- Interventions
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT03116828
- Locations
- 🇺🇸
Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Aston Ambulatory Care Center, Dallas, Texas, United States
🇺🇸Northwestern Medical Group, Deparment of Neurology, Chicago, Illinois, United States
A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Registration Number
- NCT03108729
- Locations
- 🇺🇸
Child Neurology Specialists / Clinical Research Center of Nevada, LLC, Henderson, Nevada, United States
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
- Conditions
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 491
- Registration Number
- NCT03107026
- Locations
- 🇺🇸
Lytle and Weiss PLLC, Denver, Colorado, United States
🇺🇸Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
🇺🇸Bioscience Research, LLC, Mount Kisco, New York, United States
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 1134
- Registration Number
- NCT02993731
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Montefiore Cancer Center, Bronx, New York, United States
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02826161
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02795637
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 1253
- Registration Number
- NCT02753127
- Locations
- 🇺🇸
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
🇺🇸Dana Farber, Boston, Massachusetts, United States
🇨🇦University of Toronto - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada